PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-1.10
Negative D/E while GNPX shows 0.00. Joel Greenblatt would look for hidden assets and restructuring catalysts.
-5.38
Net cash position while GNPX shows net debt of 0.29. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.
-2.74
Negative coverage while GNPX shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
1.82
Current ratio exceeding 1.5x GNPX's 0.84. Charlie Munger would verify if this advantage translates to better supplier terms.
No Data
No Data available this quarter, please select a different quarter.
